Max Parker
University of Melbourne(AU)St Vincents Institute of Medical Research(AU)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Cancer Mechanisms and Therapy, Hepatocellular Carcinoma Treatment and Prognosis, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer(2012)103 cited
- → Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor(2012)71 cited
- → Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats(2013)39 cited
- Receptor tyrosine kinase cross talk affects tumor cell sensitivity to RTK inhibitors(2008)
- → The human pi-class glutathione S-transferase: a target for structure-based drug design(1996)
- → 430 Design and structure–activity relationships of highly potent and bioavailable imidazolinone FASN KR domain inhibitors(2014)
- → Identification and structural analysis of a novel two-component toxin complex reveals the assembly of membrane pores regulated by proteolytic activation(2023)
- → Crystal structure of theLeishmania majorMIX protein(2011)